Adaptive Biotechnologies ClonoSEQ Expansion
Adaptive Biotechnologies has announced the expansion of its clonoSEQ process to include minimal residual disease analysis of cells harvested from patients with lymphoid cancers being prepared for autologous stem cell transplant. The expansion will allow physicians to prepare patients for autologous stem cell transplants by providing prognostic information that may potentially inform treatment decisions about maintenance post-transplant, Tom Willis, senior vice president and general manager of diagnostic products at Adaptive Biotechnologies, said in a statement. Physicians wishing to submit autograft samples should fill out the clonoSEQ MRD Test Requisition Form and submit samples using a clonoSEQ Specimen Kit to Adaptive's CLIA-certified, CAP-accredited laboratory in South San Francisco. Results will be available within seven days of sample receipt.